Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to compare celecoxib plus a PPI (esomeprazole) versus naproxen plus
a PPI (esomeprazole) in preventing recurrent ulcer bleeding in arthritis patients with a
history of ulcer bleeding who require concomitant ASA. We hypothesized that among patients
with a history of ulcer bleeding who require concomitant ASA, celecoxib plus esomprazole
would be superior to naproxen plus esomeprazole for the prevention of recurrent ulcer
bleeding.